8-K: Aspira Women's Health Secures $10M Equity Line

Aspira Women's Health Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $10.0 million in common stock, providing flexible capital access.

Summary

• Aspira Women's Health Inc. (the "Company") entered into a Purchase Agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") on December 23, 2025.
• Lincoln Park committed to purchase up to an aggregate of $10.0 million of the Company's common stock over a period of up to 24 months, at the Company's discretion.
• The purchase price for regular purchases will be 95% of the lower of (i) the lowest sale price on the purchase date or (ii) the average of the three lowest closing sale prices during the ten business days immediately preceding the purchase date.
• Regular purchases can be up to 50,000 shares, increasing to 75,000 shares if the closing sale price is not below $0.50, and up to 100,000 shares if not below $0.75, with a maximum dollar amount of $500,000 per regular purchase.
• Accelerated purchases are also possible, up to the lesser of (i) 300% of the corresponding regular purchase limit or (ii) 30% of the trading volume on the accelerated purchase date, at a price based on 95% of the closing sale price or volume-weighted average price.
• As consideration for Lincoln Park's commitment, the Company issued 824,493 shares of common stock (Commitment Shares) having an aggregate dollar value equal to 3.0% of the $10.0 million aggregate commitment.
• Lincoln Park has agreed not to engage in short sales or hedging transactions that establish a net short position in the Company's common stock.
• The Company is prohibited from entering into another equity line of credit or substantially similar arrangement during the 24-month term, but may enter into an at-the-market offering program.
• A registration statement will be filed with the SEC to cover the resale of shares issued to Lincoln Park.

Sentiment

Score: 7

Explanation: The agreement provides a significant and flexible source of capital for Aspira Women's Health, which is a positive for its operational stability and growth prospects. However, the potential for dilution and the discount on share sales represent a cost to existing shareholders, balancing the overall sentiment.

Positives

• Secures access to up to $10.0 million in capital, enhancing liquidity and financial flexibility.
• The Company retains sole discretion over when and if to direct Lincoln Park to purchase shares, allowing for opportunistic capital raises.
• The agreement does not impose financial or business covenants on the Company.
• There are no limitations on the use of proceeds from the share sales.
• Lincoln Park is prohibited from short selling or hedging the Company's common stock, which can help mitigate downward pressure on the stock price.
• The Company can still utilize an at-the-market (ATM) offering program with a registered broker-dealer, providing additional financing flexibility.

Negatives

• Potential for significant dilution for existing shareholders as new common stock is issued over time.
• Shares are sold at a 5% discount to market prices, which is a cost to existing shareholders.
• The issuance of 824,493 commitment shares (3.0% of the total commitment) as consideration immediately dilutes existing shareholders.
• A floor price of $0.10 per share is set for regular purchases, below which the Company cannot direct sales, potentially limiting access to capital if the stock price falls significantly.
• The Company is restricted from entering into other equity line of credit arrangements for 24 months, limiting alternative financing options of this type.

Risks

• Market price fluctuations could significantly impact the actual amount of capital the Company can raise and the extent of dilution.
• The beneficial ownership limitation (initially 4.99%, adjustable to 9.99%) for Lincoln Park and its affiliates could restrict the volume of shares purchased at any given time.
• The Company's ability to direct purchases is subject to various suspension events, including the registration statement lapsing, trading suspensions, delisting, or failure of the transfer agent to issue shares, which could interrupt access to capital.
• The Company's stock is traded on the OTC QX Market, which may have lower liquidity and higher volatility compared to major exchanges, potentially affecting the effectiveness of the financing mechanism.

Future Outlook

The agreement provides Aspira Women's Health with a flexible funding mechanism to support its operations and strategic initiatives over the next two years. The actual amount of capital raised will depend on the Company's future funding needs and its discretion to direct share sales, as well as prevailing market conditions and the Company's stock price.

Management Comments

• Michael Buhle, Chief Executive Officer, signed the Purchase Agreement and Registration Rights Agreement on behalf of Aspira Women's Health Inc. No specific notable quotes were provided in the filing.

Industry Context

Equity lines of credit are a common financing tool for smaller public companies, particularly those in the biotechnology or healthcare sectors, which often require significant capital for research, development, and commercialization. This type of financing offers flexibility by allowing companies to draw capital as needed, avoiding the immediate dilution and upfront costs associated with traditional underwritten offerings. However, it also exposes the company to market price volatility, as the effective price per share is tied to future trading prices.

Comparison to Industry Standards

• The structure of this equity line of credit, including the 5% discount on share purchases and the initial 4.99% beneficial ownership cap, is consistent with standard industry practices for such financing arrangements.
• The issuance of commitment shares as consideration is also a typical feature in these types of agreements, compensating the investor for their commitment.
• The ability to utilize an at-the-market (ATM) offering program concurrently is a common provision, allowing companies to diversify their capital raising strategies.

Stakeholder Impact

• Shareholders: Will experience potential dilution from the issuance of new common stock and the 5% discount on sales. However, the capital infusion can support the Company's operations and strategic growth, potentially benefiting long-term shareholder value.
• Company: Gains enhanced liquidity and financial flexibility, enabling it to fund ongoing operations, research and development, and other strategic initiatives without immediate, large-scale debt or equity offerings.

Next Steps

• The Company must file a new registration statement with the SEC within 10 calendar days to cover the resale of shares to be issued to Lincoln Park.
• The SEC must declare the registration statement effective, and a final prospectus must be filed, before the Company can begin directing Lincoln Park to purchase shares.
• The Company will need to manage its capital draws strategically over the 24-month period, considering market conditions and its funding needs.
• The Company must maintain its listing on the Principal Market and comply with all reporting and listing obligations.

Key Dates

Recommendation

The agreement provides Aspira Women's Health with a flexible funding source of up to $10 million, which is crucial for operational stability and potential growth initiatives. However, the mechanism involves continuous share issuances at a discount to market prices, leading to ongoing dilution for existing shareholders. While the company retains discretion over the timing and amount of sales, the long-term impact on share price will depend on how effectively this capital is deployed and the company's ability to achieve profitability and growth. Given the balance of capital access and dilution, a 'hold' recommendation is appropriate, advising investors to monitor the company's use of funds and its operational performance.

Keywords

Equity line of credit, Financing, Common stock, Capital raise, Dilution, SEC filing, Aspira Women's Health, Lincoln Park Capital, AWHL, Investment agreement